
  <style>
  .gh-table table { 
    border-collapse: collapse; 
    width: 100%;
    border: 1px solid #444;
    font-size: 12px;
  }
  .gh-table th, .gh-table td { 
    border: 1px solid #444; 
    padding: 4px 6px; 
    vertical-align: top;
    font-weight: 400 !important;   /* regular font */
  }
  .gh-table th { 
    .gh-table th { background: #f5f5f5; text-align: left; }
  }
  .gh-table th { font-weight: 700 !important; }
    @media print {
      .gh-table { font-size: 10px; }
    }
  </style>
  <div class='gh-table'><table><thead><tr><th>record_id</th><th>visit</th><th>Molecola (1)</th><th>Molecola (2)</th><th>description</th></tr></thead><tbody><tr><td>L59</td><td>1</td><td>Doravirine</td><td>Lercanidipine</td><td>The metabolism of Doravirine can be decreased when combined with Lercanidipine.</td></tr><tr><td>L59</td><td>1</td><td>Doravirine</td><td>Lercanidipine</td><td>The metabolism of Doravirine can be decreased when combined with Lercanidipine.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Lamivudine</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Enalapril is combined with Lamivudine.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Lamivudine</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Enalapril is combined with Lamivudine.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Metformin</td><td>The risk or severity of lactic acidosis can be increased when Enalapril is
combined with Metformin.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Metformin</td><td>The risk or severity of lactic acidosis can be increased when Enalapril is
combined with Metformin.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Metformin</td><td>The risk or severity of lactic acidosis can be increased when Enalapril is
combined with Metformin.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Metformin</td><td>The risk or severity of lactic acidosis can be increased when Enalapril is
combined with Metformin.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Pantoprazole</td><td>The excretion of Enalapril can be decreased when combined with Pantoprazole.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Pantoprazole</td><td>The excretion of Enalapril can be decreased when combined with Pantoprazole.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Pantoprazole</td><td>The excretion of Enalapril can be decreased when combined with Pantoprazole.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Pantoprazole</td><td>The excretion of Enalapril can be decreased when combined with Pantoprazole.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Rosuvastatin</td><td>The excretion of Rosuvastatin can be decreased when combined with Enalapril.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Rosuvastatin</td><td>The excretion of Rosuvastatin can be decreased when combined with Enalapril.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Tenofovir disoproxil</td><td>The excretion of Tenofovir disoproxil can be decreased when combined with
Enalapril.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Tenofovir disoproxil</td><td>The excretion of Tenofovir disoproxil can be decreased when combined with
Enalapril.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Tenofovir disoproxil</td><td>The excretion of Tenofovir disoproxil can be decreased when combined with
Enalapril.</td></tr><tr><td>L59</td><td>1</td><td>Enalapril</td><td>Tenofovir disoproxil</td><td>The excretion of Tenofovir disoproxil can be decreased when combined with
Enalapril.</td></tr><tr><td>L59</td><td>1</td><td>Escitalopram</td><td>Melatonin</td><td>The risk or severity of adverse effects can be increased when Melatonin is
combined with Escitalopram.</td></tr><tr><td>L59</td><td>1</td><td>Escitalopram</td><td>Metformin</td><td>The risk or severity of hypoglycemia can be increased when Escitalopram is
combined with Metformin.</td></tr><tr><td>L59</td><td>1</td><td>Escitalopram</td><td>Pantoprazole</td><td>The metabolism of Escitalopram can be decreased when combined with Pantoprazole.</td></tr><tr><td>L59</td><td>1</td><td>Escitalopram</td><td>Pioglitazone</td><td>The risk or severity of hypoglycemia can be increased when Escitalopram is
combined with Pioglitazone.</td></tr><tr><td>L59</td><td>1</td><td>Ezetimibe</td><td>Pantoprazole</td><td>Pantoprazole may decrease the excretion rate of Ezetimibe which could result in
a higher serum level.</td></tr><tr><td>L59</td><td>1</td><td>Lamivudine</td><td>Enalapril</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Enalapril is combined with Lamivudine.</td></tr><tr><td>L59</td><td>1</td><td>Lamivudine</td><td>Enalapril</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Enalapril is combined with Lamivudine.</td></tr><tr><td>L59</td><td>1</td><td>Lamivudine</td><td>Folic acid</td><td>Folic acid may decrease the excretion rate of Lamivudine which could result in a
higher serum level.</td></tr><tr><td>L59</td><td>1</td><td>Lamivudine</td><td>Lercanidipine</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Lercanidipine is combined with Lamivudine.</td></tr><tr><td>L59</td><td>1</td><td>Lamivudine</td><td>Lercanidipine</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Lercanidipine is combined with Lamivudine.</td></tr><tr><td>L59</td><td>1</td><td>Lamivudine</td><td>Metformin</td><td>Metformin may decrease the excretion rate of Lamivudine which could result in a
higher serum level.</td></tr><tr><td>L59</td><td>1</td><td>Lamivudine</td><td>Pantoprazole</td><td>Pantoprazole may decrease the excretion rate of Lamivudine which could result in
a higher serum level.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Doravirine</td><td>The metabolism of Doravirine can be decreased when combined with Lercanidipine.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Doravirine</td><td>The metabolism of Doravirine can be decreased when combined with Lercanidipine.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Lamivudine</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Lercanidipine is combined with Lamivudine.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Lamivudine</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Lercanidipine is combined with Lamivudine.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Melatonin</td><td>The therapeutic efficacy of Lercanidipine can be decreased when used in
combination with Melatonin.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Melatonin</td><td>The therapeutic efficacy of Lercanidipine can be decreased when used in
combination with Melatonin.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Metformin</td><td>The risk or severity of hypoglycemia can be increased when Lercanidipine is
combined with Metformin.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Metformin</td><td>The risk or severity of hypoglycemia can be increased when Lercanidipine is
combined with Metformin.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Metformin</td><td>The risk or severity of hypoglycemia can be increased when Lercanidipine is
combined with Metformin.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Metformin</td><td>The risk or severity of hypoglycemia can be increased when Lercanidipine is
combined with Metformin.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Pioglitazone</td><td>The risk or severity of hypoglycemia can be increased when Lercanidipine is
combined with Pioglitazone.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Pioglitazone</td><td>The risk or severity of hypoglycemia can be increased when Lercanidipine is
combined with Pioglitazone.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Rosuvastatin</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Lercanidipine is combined with Rosuvastatin.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Rosuvastatin</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Lercanidipine is combined with Rosuvastatin.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Semaglutide</td><td>The risk or severity of hypoglycemia can be increased when Lercanidipine is
combined with Semaglutide.</td></tr><tr><td>L59</td><td>1</td><td>Lercanidipine</td><td>Semaglutide</td><td>The risk or severity of hypoglycemia can be increased when Lercanidipine is
combined with Semaglutide.</td></tr><tr><td>L59</td><td>1</td><td>Melatonin</td><td>Lercanidipine</td><td>The therapeutic efficacy of Lercanidipine can be decreased when used in
combination with Melatonin.</td></tr><tr><td>L59</td><td>1</td><td>Melatonin</td><td>Lercanidipine</td><td>The therapeutic efficacy of Lercanidipine can be decreased when used in
combination with Melatonin.</td></tr><tr><td>L59</td><td>1</td><td>Melatonin</td><td>Tenofovir disoproxil</td><td>The excretion of Tenofovir disoproxil can be decreased when combined with
Melatonin.</td></tr><tr><td>L59</td><td>1</td><td>Metformin</td><td>Folic acid</td><td>Folic acid may decrease the excretion rate of Metformin which could result in a
higher serum level.</td></tr><tr><td>L59</td><td>1</td><td>Metformin</td><td>Pantoprazole</td><td>Pantoprazole may decrease the excretion rate of Metformin which could result in
a higher serum level.</td></tr><tr><td>L59</td><td>1</td><td>Metformin</td><td>Tenofovir disoproxil</td><td>Tenofovir disoproxil may decrease the excretion rate of Metformin which could
result in a higher serum level.</td></tr><tr><td>L59</td><td>1</td><td>Pantoprazole</td><td>Folic acid</td><td>Pantoprazole may decrease the excretion rate of Folic acid which could result in
a higher serum level.</td></tr><tr><td>L59</td><td>1</td><td>Pioglitazone</td><td>Lercanidipine</td><td>The risk or severity of hypoglycemia can be increased when Lercanidipine is
combined with Pioglitazone.</td></tr><tr><td>L59</td><td>1</td><td>Pioglitazone</td><td>Lercanidipine</td><td>The risk or severity of hypoglycemia can be increased when Lercanidipine is
combined with Pioglitazone.</td></tr><tr><td>L59</td><td>1</td><td>Pioglitazone</td><td>Rosuvastatin</td><td>The therapeutic efficacy of Pioglitazone can be increased when used in
combination with Rosuvastatin.</td></tr><tr><td>L59</td><td>1</td><td>Rosuvastatin</td><td>Enalapril</td><td>The excretion of Rosuvastatin can be decreased when combined with Enalapril.</td></tr><tr><td>L59</td><td>1</td><td>Rosuvastatin</td><td>Enalapril</td><td>The excretion of Rosuvastatin can be decreased when combined with Enalapril.</td></tr><tr><td>L59</td><td>1</td><td>Rosuvastatin</td><td>Lamivudine</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Lamivudine is combined with Rosuvastatin.</td></tr><tr><td>L59</td><td>1</td><td>Rosuvastatin</td><td>Lercanidipine</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Lercanidipine is combined with Rosuvastatin.</td></tr><tr><td>L59</td><td>1</td><td>Rosuvastatin</td><td>Lercanidipine</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Lercanidipine is combined with Rosuvastatin.</td></tr><tr><td>L59</td><td>1</td><td>Rosuvastatin</td><td>Melatonin</td><td>The excretion of Rosuvastatin can be decreased when combined with Melatonin.</td></tr><tr><td>L59</td><td>1</td><td>Rosuvastatin</td><td>Pantoprazole</td><td>The excretion of Rosuvastatin can be decreased when combined with Pantoprazole.</td></tr><tr><td>L59</td><td>1</td><td>Rosuvastatin</td><td>Tenofovir disoproxil</td><td>The excretion of Tenofovir disoproxil can be decreased when combined with
Rosuvastatin.</td></tr><tr><td>L59</td><td>1</td><td>Semaglutide</td><td>Escitalopram</td><td>The risk or severity of hypoglycemia can be increased when Escitalopram is
combined with Semaglutide.</td></tr><tr><td>L59</td><td>1</td><td>Semaglutide</td><td>Lercanidipine</td><td>The risk or severity of hypoglycemia can be increased when Lercanidipine is
combined with Semaglutide.</td></tr><tr><td>L59</td><td>1</td><td>Semaglutide</td><td>Lercanidipine</td><td>The risk or severity of hypoglycemia can be increased when Lercanidipine is
combined with Semaglutide.</td></tr><tr><td>L59</td><td>1</td><td>Semaglutide</td><td>Metformin</td><td>The risk or severity of hypoglycemia can be increased when Metformin is combined
with Semaglutide.</td></tr><tr><td>L59</td><td>1</td><td>Semaglutide</td><td>Pioglitazone</td><td>The risk or severity of hypoglycemia can be increased when Pioglitazone is
combined with Semaglutide.</td></tr><tr><td>L59</td><td>1</td><td>Semaglutide</td><td>Rosuvastatin</td><td>The therapeutic efficacy of Semaglutide can be increased when used in
combination with Rosuvastatin.</td></tr><tr><td>L59</td><td>1</td><td>Tenofovir disoproxil</td><td>Folic acid</td><td>Tenofovir disoproxil may decrease the excretion rate of Folic acid which could
result in a higher serum level.</td></tr><tr><td>L59</td><td>1</td><td>Tenofovir disoproxil</td><td>Pantoprazole</td><td>The excretion of Tenofovir disoproxil can be decreased when combined with
Pantoprazole.</td></tr></tbody></table></div>
